Provenance Record

Excellent, disciplined clinical News piece (627 words) on the Phase 3 INDIGO readout — every endpoint attributed to a specific press release, with the NEJM publication cited only for the publication fact and the full safety/durability caveats clearly stated.

Four of five snapshots read from disk (HTTP 200). source-0 (GlobeNewswire) confirms the 56% flare-risk reduction, 194 patients, 250 mg subcutaneous weekly for 52 weeks, the bifunctional CD19/FcγRIIb mechanism, 37.1% vs 19.6% complete remission, the 329.5 mg vs 929.8 mg glucocorticoid figures, the EULAR June 4 London presentation, and both quotes (Lisa von Moltke's 'largest clinical trial ever conducted in IgG4-RD' and Emanuel Della Torre's 'novel, highly active, self-administered therapy', with his Vita-Salute San Raffaele affiliation). source-1 (StockTitan) confirms HR 0.44 (95% CI 0.277-0.711; p=0.0005), 73.2% vs 45.4% flare-free, grade ≥3 TEAEs 11.3% vs 23.7%, SAEs 10.3% vs 18.6%, the May 2026 BLA, and the 'B cell lineage' detail. source-2 (BioSpace) confirms the secondary-endpoint statistics (HR 0.41, 95% CI 0.26-0.66, p=0.0001, 59%; HR 0.48, 95% CI 0.32-0.74, p=0.0008, 52%; p=0.0049; the 65% steroid reduction). source-4 (NCBI StatPearls) confirms the disease background (pancreas/retroperitoneum organ involvement, corticosteroid mainstay, 'Relapse rates are between 10% to 53%'). source-3 (NEJM) returned HTTP 403 (bot-blocked).

Every statistic — relative reductions, hazard ratios, confidence intervals, p-values, remission rates, glucocorticoid totals, and safety percentages — is verbatim in the specific outlet it is cited to, with disciplined single-outlet attribution and no compound citations. The NEJM 403 is correctly handled per Rule 9: NEJM is cited only for the DOI/publication fact, which is corroborated by GlobeNewswire; no numeric claim depends on the blocked source.

High-quality, fully-verified medical submission with exemplary statistic attribution and correct handling of the bot-blocked primary publication. APPROVE.